Q2 Earnings Forecast for CATX Issued By Wedbush

Key Points

• Wedbush forecasts that Perspective Therapeutics, Inc. (NYSE:CATX) will report a Q2 2026 earnings per share (EPS) of ($0.38), maintaining an "Outperform" rating with a price target of $11.00.
• Despite a mixed range of price targets from various brokerages, the consensus price target for CATX currently stands at $12.56, reflecting a majority "buy" rating from analysts.
• CATX shares recently traded at $3.73, and the company has seen significant institutional interest, with hedge funds owning approximately 54.66% of the stock.

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Investment analysts at Wedbush issued their Q2 2026 EPS estimates for Perspective Therapeutics in a report issued on Wednesday, August 13th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.38) per share for the quarter. Wedbush currently has a "Outperform" rating and a $11.00 target price on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. Wedbush also issued estimates for Perspective Therapeutics' Q3 2026 earnings at ($0.38) EPS and Q4 2026 earnings at ($0.39) EPS.

A number of other research firms also recently issued reports on CATX. Truist Financial dropped their price objective on shares of Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a research report on Saturday, July 12th. B. Riley restated a "buy" rating and set a $12.00 price target (up previously from $9.00) on shares of Perspective Therapeutics in a research report on Monday, June 23rd. Finally, Royal Bank Of Canada upgraded Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and raised their price target for the company from $15.00 to $16.00 in a research report on Tuesday, June 3rd. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $12.56.

Perspective Therapeutics Price Performance

NYSE CATX traded down $0.04 during trading on Friday, reaching $3.38. The company's stock had a trading volume of 497,034 shares, compared to its average volume of 945,307. The firm has a fifty day moving average of $3.77 and a 200 day moving average of $2.96. Perspective Therapeutics has a one year low of $1.60 and a one year high of $16.55.

Hedge Funds Weigh In On Perspective Therapeutics

Hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its stake in shares of Perspective Therapeutics by 498.3% during the 4th quarter. JPMorgan Chase & Co. now owns 149,045 shares of the company's stock valued at $475,000 after purchasing an additional 124,133 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Perspective Therapeutics by 45.7% in the fourth quarter. Wells Fargo & Company MN now owns 26,462 shares of the company's stock worth $84,000 after buying an additional 8,294 shares during the period. Mariner LLC bought a new stake in Perspective Therapeutics during the 4th quarter valued at approximately $150,000. Walleye Capital LLC boosted its position in Perspective Therapeutics by 2,526.2% during the 4th quarter. Walleye Capital LLC now owns 475,792 shares of the company's stock valued at $1,518,000 after acquiring an additional 457,675 shares in the last quarter. Finally, Jump Financial LLC purchased a new position in shares of Perspective Therapeutics during the 4th quarter worth approximately $688,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.